{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:30Z","timestamp":1791920910382,"version":"4.3.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971949 , 82071354"],"award-info":[{"award-number":["81971949 , 82071354"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A simple and clinically applicable prognostic scoring system for AIDS-related lymphoma (ARL) in the era of combination antiretroviral therapy (cART) is needed to better stratify patients\u2019 risks and to assist in the decision-making of therapeutic strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective multicenter cohort study in 138 primary ARL patients over an 8-year period from 2013 to 2020. Survival curves were estimated using the Kaplan\u2013Meier method. Univariate and multivariate Cox proportional hazard models were performed to identify the association between patient-, lymphoma-, and HIV-specific variables with progression-free survival (PFS) and overall survival (OS). The incremental prognostic value of novel inflammatory biomarkers in the International Prognostic Index (IPI) was evaluated by comparing the receiver operating characteristic (ROC) curves, the concordance index (C-index), and the integrated Brier score (IBS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 49.14 \u00b1 14.20 (range 18\u201379) years, 81.9% were men, and the median follow-up was 44.94 (95% CI = 37.05\u201352.84) months. The 3-year OS and PFS were 39.4% (95% CI = 16.3\u201321.2) and 38.7% (95% CI = 14.5\u201319.7), respectively. We found that age, extranodal sites, bulky mass, CD4 T-cell counts, CD4\/CD8 ratio, and hypoalbuminemia were associated with OS (all <jats:italic>P<\/jats:italic> &amp;lt; 0.05) at both univariate and multivariate analyses. Of the new inflammatory markers, only the CD4\/CD8 ratio was an independent prognostic parameter of OS and PFS. A lower CD4\/CD8 ratio was strongly associated with adverse clinical factors, including older age, advanced Ann Arbor stage, more extranodal sites, elevated erythrocyte sedimentation rate, prior history of HIV, higher red cell distribution width ratio, hypoproteinemia, and emaciation. When the CD4\/CD8 ratio was added to the IPI, the composite HIV-IPI score showed significantly better discrimination than IPI alone [AUC (95% CI): HIV-IPI, 0.83 (0.77\u20130.89) vs. IPI, 0.72 (0.70\u20130.85)]. The HIV-IPI model provided good predictive performance [C-index (95% CI): HIV-IPI, 0.82 (0.81\u20130.83) vs. IPI, 0.75 (0.73\u20130.77), <jats:italic>P<\/jats:italic> &amp;lt; 0.001] and a satisfactory calibration function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The CD4\/CD8 ratio, an inexpensive and readily available marker, is a powerful independent prognostic parameter in patients with ARL. Furthermore, when the CD4\/CD8 ratio is used in combination with IPI, it increases prognostic ability. The useful prediction of expected outcomes in ARL can inform treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.919446","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T17:22:53Z","timestamp":1657128173000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A Novel Prognostic Score Including the CD4\/CD8 for AIDS-Related Lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Juanjuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanfang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjing","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiman","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1182\/bloodadvances.2021004458","article-title":"HIV-Associated Burkitt Lymphoma: Outcomes From a US-UK Collaborative Analysis","volume":"5","author":"Alderuccio","year":"2021","journal-title":"Blood Adv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the Influence of Lymphoma- and HIV-Specific Factors on Outcomes in AIDS-Related Non-Hodgkin Lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","article-title":"A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab-Era","volume":"99","author":"Barta","year":"2014","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16263","article-title":"New Prognosis Score Including Absolute Lymphocyte\/monocyte Ratio, Red Blood Cell Distribution Width and Beta-2 Microglobulin in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)","volume":"188","author":"Bento","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ageing\/afx013","article-title":"Frailty and Physical Function in Older HIV-Infected Adults","volume":"46","author":"Branas","year":"2017","journal-title":"Age Ageing"},{"key":"B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/cid\/ciaa1137","article-title":"CD4\/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies","volume":"73","author":"Caby","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00277-021-04474-3","article-title":"Circulating Low CD4(+)\/CD8(+) Ratio is Associated With Poor Prognosis in Waldenstrom Macroglobulinemia Patients","volume":"100","author":"Cao","year":"2021","journal-title":"Ann. Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S2352-3018(17)30027-9","article-title":"CD4\/CD8 Ratio and Lung Cancer Risk","volume":"4","author":"Clifford","year":"2017","journal-title":"Lancet HIV"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1182\/blood-2009-02-204172","article-title":"Hodgkin Lymphoma in the Swiss HIV Cohort Study","volume":"113","author":"Clifford","year":"2009","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006285","article-title":"Levels of HIV-1 Persistence on Antiretroviral Therapy Are Not Associated With Markers of Inflammation or Activation","volume":"13","author":"Gandhi","year":"2017","journal-title":"PloS Pathog."},{"key":"B11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in Combination With Intravenous Rituximab (REVRI) in Relapsed\/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: A Multicenter Prospective 'Proof of Concept' Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-Cell Immune Effectors and Checkpoint Molecules as Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: A Population-Based Study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","article-title":"Epidemiology of Haematological Malignancies in People Living With HIV","volume":"7","author":"Kimani","year":"2020","journal-title":"Lancet HIV"},{"key":"B15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/jamadermatol.2021.5119","article-title":"Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: The Role of Novel Inflammatory Markers and Proposed Revision of SCORTEN (Re-SCORTEN)","volume":"158","author":"Koh","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ajh.26149","article-title":"Relapsed\/Refractory International Prognostic Index (R\/R-IPI): An International Prognostic Calculator for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"96","author":"Maurer","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006624","article-title":"Imbalance in the Game of T Cells: What Can the CD4\/CD8 T-Cell Ratio Tell Us About HIV and Health","volume":"13","author":"Mcbride","year":"2017","journal-title":"PloS Pathog."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 Ratio Normalisation and Non-AIDS-Related Events in Individuals With HIV Who Achieve Viral Load Suppression With Antiretroviral Therapy: An Observational Cohort Study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing Treatment of HIV-Associated Lymphoma","volume":"134","author":"NOY","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.1016\/S2352-3018(20)30227-7","article-title":"HIV and Lymphoma: From Oncological Futility to Treatment","volume":"7","author":"NOY","year":"2020","journal-title":"Lancet HIV"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1158\/1078-0432.CCR-14-0889","article-title":"T-Cell Levels Are Prognostic in Mantle Cell Lymphoma","volume":"20","author":"Nygren","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of Myc in HIV-Associated Non-Hodgkin Lymphomas Treated With EPOCH and Outcomes With Vorinostat (AMC-075 Trial)","volume":"136","author":"Ramos","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2352-3026(20)30115-0","article-title":"Treatment Management of Haematological Malignancies in People Living With HIV","volume":"7","author":"Re","year":"2020","journal-title":"Lancet Haematology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International Prognostic Indices in Diffuse Large B-Cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2017.180893","article-title":"Incidence and Risk Factors for Relapses in HIV-Associated Non-Hodgkin Lymphoma As Observed in the German HIV-Related Lymphoma Cohort Study","volume":"103","author":"Schommers","year":"2018","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1016\/S2352-3018(20)30202-2","article-title":"Effects of First-Line Antiretroviral Therapy on the CD4\/CD8 Ratio and CD8 Cell Counts in CoRIS: A Prospective Multicentre Cohort Study","volume":"7","author":"Serrano-villar","year":"2020","journal-title":"Lancet HIV"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3018(16)30215-6","article-title":"Immunological and Infectious Risk Factors for Lung Cancer in US Veterans With HIV: A Longitudinal Cohort Study","volume":"4","author":"Sigel","year":"2017","journal-title":"Lancet HIV"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-Associated Cancers and Related Diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl. J. Med."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.919446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T17:22:55Z","timestamp":1657128175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.919446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":28,"alternative-id":["10.3389\/fcimb.2022.919446"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.919446","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"article-number":"919446"}}